Literature DB >> 17587822

Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition.

Miroslav Blumenberg1, Shujuan Gao, Kathleen Dickman, Arthur P Grollman, Erwin P Bottinger, Jiri Zavadil.   

Abstract

Epithelial-mesenchymal transitions (EMTs) occur in organogenesis throughout embryonic development and are recapitulated during epithelial tissue injury and in carcinoma progression. EMTs are regulated by complex, precisely orchestrated cell signaling and gene expression networks, with the participation of key developmental pathways. Here we review context-dependent modules of gene regulation by hairy/enhancer-of-split-related (H/E(spl)) repressors downstream of transforming growth factor-beta (TGF-beta)/Smad and Notch signals in EMT and in other phenotype transitions such as differentiation and cancer. Based on multiple models of disease-related EMT, we propose that Polycomb group epigenetic silencers and histone-lysine methyl-transferases EZH1 and EZH2 are candidate targets of H/E(spl)-mediated transcriptional repression, in a process accompanied by replacement of modified core histone H3 with de novo synthesized histone variant H3.3B. Finally, we discuss the potential significance of this scenario for EMT in the light of recent findings on gene regulation by histone modifications and chromatin structure changes. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587822     DOI: 10.1159/000101317

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  9 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease.

Authors:  Davoud Mohtat; Rosemary Thomas; Zangfang Du; Yaa Boakye; Thomas Moulton; Catherine Driscoll; Robert Woroniecki
Journal:  Pediatr Nephrol       Date:  2010-11-25       Impact factor: 3.714

3.  Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.

Authors:  Matthew D Taylor; Yuan Liu; Alykhan S Nagji; Nicholas Theodosakis; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05       Impact factor: 5.209

4.  The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.

Authors:  Li-Bing Song; Jun Li; Wen-Ting Liao; Yan Feng; Chun-Ping Yu; Li-Juan Hu; Qing-Li Kong; Li-Hua Xu; Xing Zhang; Wan-Li Liu; Man-Zhi Li; Ling Zhang; Tie-Bang Kang; Li-Wu Fu; Wen-Lin Huang; Yun-Fei Xia; Sai Wah Tsao; Mengfeng Li; Vimla Band; Hamid Band; Qing-Hua Shi; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

5.  Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology.

Authors:  Kuo-Jung Su; Chiao-Wen Lin; Mu-Kuan Chen; Shun-Fa Yang; Yung-Luen Yu
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 6.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

7.  Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.

Authors:  Francesco Crea; Elaine M Hurt; Lesley A Mathews; Stephanie M Cabarcas; Lei Sun; Victor E Marquez; Romano Danesi; William L Farrar
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

8.  MeCP2-421-mediated RPE epithelial-mesenchymal transition and its relevance to the pathogenesis of proliferative vitreoretinopathy.

Authors:  Xiaohua Li; Xue Li; Shikun He; Mingwei Zhao
Journal:  J Cell Mol Med       Date:  2020-07-08       Impact factor: 5.310

9.  Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.

Authors:  Juan F Santibanez
Journal:  ISRN Dermatol       Date:  2013-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.